Benseler, Susanne M.

Currie, G.

Grazziotin Lago, L.

IJzerman, M.J.

Kip, M.

Marshall, D.

Swart, J.F.

Twilt, M.

van den Berg, I.

English

University of Twente Research Information

€ 0 € 5.000 € 10.000 € 15.000JIA undifferentiated (n = 10)Oligoarticular persistent JIA, ANA - (n = 164)Psoriatic JIA (n = 34)Oligoarticular persistent JIA, ANA + (n = 168)JIA uveitis (n = 57)Polyarticular JIA RF - (n = 167)Enthesitis related JIA (n = 75)Extended oligoarticular JIA (n = 84)Polyarticular JIA RF + (n = 38)Systemic JIA (n = 87)MedicationAdmissionsConsultationsLaboratory testsImagingOperationsED visitsJuvenile idiopathic arthritis (JIA) is associated with considerable financial burden to society: results of a Dutch cost analysisInge van den Berg1, Michelle M.A. Kip1, Deborah A. Marshall2, Gillian Currie3, Luiza Grazziotin Lago2, Marinka Twilt4, Susanne M. Benseler4, Sytze de Roock5, Annet van Royen5, Joost F. Swart5, Sebastiaan J. Vastert5, Nico Wulffraat5, Rae S.M. Yeung6, Maarten J. IJzerman1, on behalf of the UCAN CAN-DU health economics working group* of the UCAN CAN-DU project 1Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands, 2Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada, 3Department of Paediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada, 4Division of Rheumatology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada, 5Department of Pediatric Rheumatology, Division of Paediatrics, University Medical Center Utrecht, Wilhelmina Children’s Hospital, Utrecht, The Netherlands, 6Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.ObjectiveJIA is the most common chronic rheumatologic disease in childhood. Aim: to determine the cost impact of JIA, from a hospital and a societal perspective, and investigate cost differences between JIA subtypes.Data analysed: • Retrospective cohort of 884 JIA patients (0-18 years), treated in the Wilhelmina Children’s Hospital (NL), between 04/2011 and 04/2019. • Including: medication use, imaging, laboratory tests, admissions, operations, consultations, and emergency department visits.Costs of hospital-related resource were obtained from hospital tariffs, the Dutch Healthcare Authority, the Dutch Pharmacotherapeutic Compass, and the Dutch pediatric formulary.Out-of-pocket costs (including other medical costs) and productivity losses were derived from studies identified in a literature review [1].Results• Mean annual hospital-related costs (including medication): €5361/patient. • Highest annual hospital-related costs (i.e. €13,548/patient) were found in systemic JIA (9.8% of patients):o €8676/patient (i.e. 64%) is attributable to medication use vs. €2583/patient in other JIA subtypes.o High costs mainly due to using biologics as first-line treatment.• Based on literature:o Annual productivity losses of patients and parents: €6491/patient.o Out-of-pocket and other medical costs: €1711/patient.Conclusion and discussion• Costs were found to vary substantially between JIA subtypeso Annual hospital-related costs were highest among systemic JIA, largely attributable to medication use. • When considering the societal perspective, productivity losses were the main cost driver.o However, evidence in literature was limited and not specified per JIA subtype.• To capture the full impact of JIA, future research should also incorporate its (wider) impacts on society. Figure 1. Distribution of average yearly costs per patient into hospital-related costs (including medication), out-of-pocket costs (including other medical costs) and productivity losses (of patients and parents).Results*Health Economics Working Group: Gouke Bonsel, Brian M. Feldman, Esther Hoppenreijs, Bianca Lang, Claire LeBlanc, Karine Toupin-April, Philomine van Pelt.MethodsFigure 2: average annual hospital-related costs (including medication) depending on JIA subtype.39,5%12,6%47,9%Medical costsOut-of-pocket costsProductivity lossesHospital-related costs € 5361t- f- ck t c sts € 1711r ti it  l € 6491Questions or more information?m.m.a.kip@utwente.nlwww.ucancandu.com[1] Kip, M.M.A., et al. (2019). Pediatr Rheumatol Online J 17(1): 20.

Juvenile idiopathic arthritis (JIA) is associated with considerable financial burden to society: results of a Dutch cost analysis

https://ris.utwente.nl/ws/files/157561015/Poster_UCAN_CANDU_ISPORCopenhagen_SocietalCosts_JIA.pdf

Juvenile idiopathic arthritis (JIA) is associated with considerable financial burden to society: results of a Dutch cost analysis

Abstract

Similar works

Full text

Available Versions

University of Twente Research Information